Subscribe
COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

Mayo Clinic Talks

COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

This episode was recorded on June 5, 2020.To claim credit visit: https://ce.mayo.edu/covid19podcastGuest: Raymund R. Razonable, M.D. (@RazonableMD)Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006) Up to about 50% of people infected with…
June 8, 2020
ADVERTISEMENT
DOCSF21

COVID-19 Miniseries Episode 36: A Comprehensive Update on COVID-19

This episode was recorded on June 5, 2020.

To claim credit visit: https://ce.mayo.edu/covid19podcast

Guest: Raymund R. Razonable, M.D. (@RazonableMD)

Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006

Up to about 50% of people infected with SARS-CoV-2 are asymptomatic spreaders. About 80% of those who are symptomatic, developing COVID-19, have mild disease displaying dry cough, fever, and fatigue. The resulting 20% of symptomatic patients accounts for those who develop progressive respiratory distress and sometimes multi-organ failure, among other complications. We’re learning more about anosmia, cardiac injury, and “COVID-toes.” What’s known about COVID-19 and SARS-CoV-2 continues to evolve. Dr. Raymund Razonable walks through a recently published update on the management of COVID-19. 

Time Stamps:1:18 – New signs and symptoms of COVID-19. 3:30 – Testing characteristics (sensitivity, specificity, and indications)  of the molecular and serologic testing for SARS-CoV-26:22 – Risk factors and the prediction of disease progression for patients hospitalized with COVID-199:28 – Hyper-inflammatory syndrome and progression to multi-system organ failure syndrome10:45 – Multisystem inflammatory syndrome in children (MIS-C) 11:22 – Cardiac complications – 3 factors12:50 – Diagnosis and treatment of co-infection in hospitalized patients (COVID-19 and flu, COVID-19 and pneumonia)16:31 – Evidence-based treatment based on the 3 phases of COVID-19 viremic phase, pneumonic phase, hyperinflammation phase18:06 – Remdesivir update21:00 – Hydroxychloroquine update23:25 – Favipiravir and lopinavir-ritonavir update23:53 – Treatment of the hyperinflammatory phase (sarilumab, tocilizumab, lenzilumab, anakinra,)27:13 – Convalescent plasma28:04 – Discharge and social determinants of health33:40 – Telehealth and remote monitoring35:40 – Health disparities and telehealth37:47 – What’s the next development Infectious Disease specialists are looking for in relation to the COVID-19 pandemic?

See the article here:A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease-19 in the Hospital Setting https://doi.org/10.1016/j.mayocp.2020.05.010

AskMayoExpert COVID-19 Resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd

ADVERTISEMENT
DOCSF21

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

Get HealthHealthXL